A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic endometriosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2019
At a glance
- Drugs Vilaprisan (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Acronyms VILLENDO
- Sponsors Bayer
- 23 Jan 2019 This trial has been suspended in Sweden.
- 08 Jan 2019 This trial has been suspended in Denmark.
- 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.